Jan C. M. van der Hoeven
Directeur/Membre du Conseil chez PamGene BV
Profil
Jan C.
M.
van der Hoeven is currently a Director-Supervisory Board at PamGene BV, Glycostem Therapeutics BV, and Dutch Life Sciences Coöperatie UA, as well as an Investment Manager at Westertoren Innovation Ventures BV.
He previously served as a Director-Supervisory Board at Immunovo BV, Member-Supervisory Board at Pepscan Therapeutics BV, InteRNA Technologies BV, Newtricious BV, and LAVA Therapeutics NV.
He also worked as a Managing Partner at Biox Biosciences BV and a Scientist at Wageningen University.
Mr. van der Hoeven obtained his undergraduate degree from Wageningen University.
Postes actifs de Jan C. M. van der Hoeven
| Sociétés | Poste | Début |
|---|---|---|
PamGene BV
 PamGene BV Pharmaceuticals: MajorHealth Technology PamGene BV provides biopharmaceutical products and clinical settings. It also provides PamChip biomarkers, such as tyrosine kinases, serine/threonine kinases, nuclear receptors, and reagent kits. The firm provides BioNavigator, a software tool for interpretation of PamChip measurements, as well as for performing data analysis for various PamChip experiments; and Evolve that enables data capture and analysis, as well as for the export of data into third party software formats. The company was founded by Tim Kievits in December 1999 and is headquartered in 's-Hertogenbosch, the Netherlands. | Directeur/Membre du Conseil | 21/10/2009 |
Biox Biosciences BV
 Biox Biosciences BV Investment ManagersFinance BioX Biosciences BV (BioX) is an privately owned venture capital firm with its headquarters in s-Hertogenbosch, The Netherlands. The firm was established in 1983. | Private Equity Investor | 05/10/2010 |
Westertoren Innovation Ventures BV
 Westertoren Innovation Ventures BV Investment ManagersFinance Westertoren Innovation Ventures BV (Westertoren Innovation Ventures) is a private equity and venture capital subsidiary of Biox Biosciences BV headquartered in 's-Hertogenbosch, Netherlands. The firm was founded in 2009. | Private Equity Investor | 05/10/2010 |
Glycostem Therapeutics BV
 Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | Directeur/Membre du Conseil | - |
Dutch Life Sciences Coöperatie UA
 Dutch Life Sciences Coöperatie UA Miscellaneous Commercial ServicesCommercial Services Dutch Life Sciences Coöperatie UA is a company based in 's-Hertogenbosch, Netherlands. The company provides services to Dutch family offices by onboarding skills in the field of business, intellectual property, finance, and marketing and communication. The company collaborates with specialists to accelerate life sciences and make a difference. The company uses cookies to enhance the user experience on their website and also uses content and scripts from third parties. Eveline Hogenkamp-van Velp has been the CEO of the company since 2019. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jan C. M. van der Hoeven
| Sociétés | Poste | Fin |
|---|---|---|
| LAVA THERAPEUTICS N.V. | Directeur/Membre du Conseil | - |
| Wageningen University | Corporate Officer/Principal | - |
Newtricious BV
 Newtricious BV Food: Major DiversifiedConsumer Non-Durables Newtricious BV develops active food ingredients and products for health maintenance. It focuses on health areas, such as, obesity, metabolic syndrome, eye health, cardiovascular health, and diabetes. The company was founded by Jos Nelissen and Marieëtte Nelissen in 2006 and is headquartered in Oirlo, the Netherlands. | Directeur/Membre du Conseil | - |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Directeur/Membre du Conseil | - |
| ░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Jan C. M. van der Hoeven
| Wageningen University | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LAVA THERAPEUTICS N.V. | Health Technology |
| Entreprise privées | 9 |
|---|---|
PamGene BV
PamGene BV Pharmaceuticals: MajorHealth Technology PamGene BV provides biopharmaceutical products and clinical settings. It also provides PamChip biomarkers, such as tyrosine kinases, serine/threonine kinases, nuclear receptors, and reagent kits. The firm provides BioNavigator, a software tool for interpretation of PamChip measurements, as well as for performing data analysis for various PamChip experiments; and Evolve that enables data capture and analysis, as well as for the export of data into third party software formats. The company was founded by Tim Kievits in December 1999 and is headquartered in 's-Hertogenbosch, the Netherlands. | Health Technology |
Biox Biosciences BV
Biox Biosciences BV Investment ManagersFinance BioX Biosciences BV (BioX) is an privately owned venture capital firm with its headquarters in s-Hertogenbosch, The Netherlands. The firm was established in 1983. | Finance |
Pepscan Therapeutics BV
 Pepscan Therapeutics BV Pharmaceuticals: MajorHealth Technology Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands. | Health Technology |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
Westertoren Innovation Ventures BV
Westertoren Innovation Ventures BV Investment ManagersFinance Westertoren Innovation Ventures BV (Westertoren Innovation Ventures) is a private equity and venture capital subsidiary of Biox Biosciences BV headquartered in 's-Hertogenbosch, Netherlands. The firm was founded in 2009. | Finance |
Immunovo BV
 Immunovo BV BiotechnologyHealth Technology Immunovo BV develops immune therapeutics in the field of oncology. The firm's research focuses on therapeutic vaccines based on synthetic peptide antigens for which the company applies the novel and proprietary techniques in synthetic immunogen development. Its products include Sclerostin, PD1, PEPA10-adj, Gastrine, VEGF, and GnRH. The company was founded in 2009 and is headquartered in ‘s-Hertogenbosch, the Netherlands. | Health Technology |
Newtricious BV
Newtricious BV Food: Major DiversifiedConsumer Non-Durables Newtricious BV develops active food ingredients and products for health maintenance. It focuses on health areas, such as, obesity, metabolic syndrome, eye health, cardiovascular health, and diabetes. The company was founded by Jos Nelissen and Marieëtte Nelissen in 2006 and is headquartered in Oirlo, the Netherlands. | Consumer Non-Durables |
Glycostem Therapeutics BV
Glycostem Therapeutics BV BiotechnologyHealth Technology Glycostem Therapeutics BV operates as a life science company which develops cellular immunotherapy and production technology platforms. It develops cellular immunotherapeutic for the treatment of leukemia, lymphomas, and other forms of cancer. The firm provides Prototype NK-cell and NK-cell progenitor cell products for clinical evaluations and intervention studies; and GBGM, a cell survival and minimal cellular delineation in expansion and differentiation experiments. The company was founded by Dirk Groenewegen and Jan van der Hoeven in 2007 and is headquartered in Oss, the Netherlands. | Health Technology |
Dutch Life Sciences Coöperatie UA
Dutch Life Sciences Coöperatie UA Miscellaneous Commercial ServicesCommercial Services Dutch Life Sciences Coöperatie UA is a company based in 's-Hertogenbosch, Netherlands. The company provides services to Dutch family offices by onboarding skills in the field of business, intellectual property, finance, and marketing and communication. The company collaborates with specialists to accelerate life sciences and make a difference. The company uses cookies to enhance the user experience on their website and also uses content and scripts from third parties. Eveline Hogenkamp-van Velp has been the CEO of the company since 2019. | Commercial Services |